Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agent like atezolimumab for use in patients with advanced stage urothelial carcinoma. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as im...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Vivek, Chaudhary, Neha, Garg, Mohit, Floudas, Charalampos S., Soni, Parita, Chandra, Abhinav B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296331/
https://www.ncbi.nlm.nih.gov/pubmed/28228726
http://dx.doi.org/10.3389/fphar.2017.00049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296331/
https://www.ncbi.nlm.nih.gov/pubmed/28228726
http://dx.doi.org/10.3389/fphar.2017.00049

Ejemplares similares